Profile data is unavailable for this security.
About the company
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, Masofaniten (formerly EPI-7386), is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). Masofaniten is in development in combination with antiandrogen treatments in patients with prostate cancer who are earlier in their course of the disease. The Company is completing the clinical development of masofaniten as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).
- Revenue in USD (TTM)0.00
- Net income in USD-27.67m
- Incorporated2009
- Employees50.00
- LocationESSA Pharma Inc999 West Broadway, Suite 720VANCOUVER V5Z 1K5CanadaCAN
- Phone+1 (778) 331-0962
- Fax+1 (778) 331-0962
- Websitehttps://www.essapharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mersana Therapeutics Inc | 29.94m | -104.77m | 268.66m | 123.00 | -- | 31.88 | -- | 8.97 | -0.8648 | -0.8648 | 0.2469 | 0.0687 | 0.1222 | -- | 38.14 | 243,390.30 | -42.75 | -61.68 | -59.36 | -81.35 | -- | -- | -349.98 | -622.19 | -- | -- | 0.7508 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
| Black Diamond Therapeutics Inc | 0.00 | -80.55m | 270.09m | 54.00 | -- | 2.43 | -- | -- | -1.54 | -1.54 | 0.00 | 1.97 | 0.00 | -- | -- | 0.00 | -59.70 | -40.29 | -67.82 | -43.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.57 | -- | -15.37 | -- |
| Vanda Pharmaceuticals Inc. | 182.02m | -10.93m | 271.05m | 203.00 | -- | 0.4996 | -- | 1.49 | -0.1886 | -0.1886 | 3.15 | 9.31 | 0.2815 | 9.96 | 4.82 | 896,660.10 | -1.69 | 6.61 | -1.97 | 7.62 | 93.03 | 90.55 | -6.00 | 15.18 | 4.67 | -- | 0.00 | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
| Zura Bio Ltd | 0.00 | -27.94m | 274.23m | 14.00 | -- | 1.75 | -- | -- | -0.4944 | -0.4944 | 0.00 | 2.46 | 0.00 | -- | -- | 0.00 | -23.00 | -- | -30.30 | -- | -- | -- | -- | -- | -- | -- | 0.0136 | -- | -- | -- | -2,050.99 | -- | -- | -- |
| Chromadex Corp | 85.58m | -1.35m | 280.95m | 106.00 | -- | 9.09 | -- | 3.28 | -0.018 | -0.018 | 1.14 | 0.407 | 1.60 | 2.86 | 12.93 | 807,386.80 | -2.52 | -42.11 | -3.85 | -65.14 | 60.82 | 59.68 | -1.58 | -30.64 | 2.12 | -- | 0.0006 | -- | 15.99 | 21.50 | 70.15 | -- | -36.66 | -- |
| AVITA Medical Inc | 54.14m | -49.83m | 281.47m | 207.00 | -- | 11.75 | -- | 5.20 | -1.95 | -1.95 | 2.12 | 0.9216 | 0.6217 | 1.46 | 7.23 | 261,541.10 | -57.22 | -- | -68.00 | -- | 86.80 | -- | -92.04 | -- | 4.81 | -13.95 | 0.6315 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
| Artiva Biotherapeutics Inc | -100.00bn | -100.00bn | 284.89m | 82.00 | -- | -- | -- | -- | -- | -- | -- | 1.09 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0087 | -- | 579.21 | -- | 51.15 | -- | -- | -- |
| ESSA Pharma Inc | 0.00 | -27.67m | 287.51m | 50.00 | -- | 2.23 | -- | -- | -0.6257 | -0.6257 | 0.00 | 2.90 | 0.00 | -- | -- | 0.00 | -19.33 | -23.01 | -19.81 | -23.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.27 | -- | -- | -- |
| Akebia Therapeutics Inc | 174.50m | -40.44m | 288.09m | 167.00 | -- | -- | -- | 1.65 | -0.2024 | -0.2024 | 0.8803 | -0.1608 | 0.7364 | 1.36 | 7.07 | 1,044,892.00 | -17.07 | -37.42 | -29.47 | -56.00 | 82.59 | 69.13 | -23.18 | -82.25 | 0.8222 | -4.41 | 8.89 | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
| Tectonic Therapeutic Inc | 0.00 | -58.25m | 291.74m | 13.00 | -- | 1.75 | -- | -- | -18.52 | -18.52 | 0.00 | 11.29 | 0.00 | -- | -- | 0.00 | -35.55 | -45.22 | -40.16 | -49.14 | -- | -- | -- | -- | -- | -128.75 | 0.0066 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
| Kyverna Therapeutics Inc | -100.00bn | -100.00bn | 298.58m | 112.00 | -- | 0.8953 | -- | -- | -- | -- | -- | 7.73 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0042 | -- | -100.00 | -- | -108.93 | -- | -- | -- |
| Tscan Therapeutics Inc | 12.20m | -104.41m | 298.77m | 175.00 | -- | 1.17 | -- | 24.49 | -1.05 | -1.05 | 0.1225 | 4.82 | 0.0353 | -- | -- | 79,220.78 | -30.19 | -- | -33.78 | -- | -- | -- | -855.84 | -- | -- | -- | 0.1066 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
| PepGen Inc | 0.00 | -89.14m | 304.71m | 64.00 | -- | 1.95 | -- | -- | -3.30 | -3.30 | 0.00 | 4.78 | 0.00 | -- | -- | 0.00 | -47.47 | -- | -52.97 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
| Heron Therapeutics Inc | 136.36m | -48.13m | 306.37m | 126.00 | -- | -- | -- | 2.25 | -0.3249 | -0.3249 | 0.9094 | -0.2503 | 0.6503 | 1.08 | 1.81 | 1,082,230.00 | -22.95 | -53.55 | -38.15 | -71.24 | 65.49 | 52.52 | -35.29 | -170.12 | 1.85 | -- | 1.34 | -- | 17.99 | 10.40 | 39.26 | -- | -29.97 | -- |
| Solid Biosciences Inc | 0.00 | -90.69m | 308.76m | 88.00 | -- | 1.60 | -- | -- | -3.30 | -3.30 | 0.00 | 5.01 | 0.00 | -- | -- | 0.00 | -41.63 | -49.99 | -44.77 | -56.25 | -- | -- | -- | -2,117.05 | -- | -- | 0.0076 | -- | -100.00 | -- | -11.67 | -- | -27.90 | -- |
Data as of Sep 20 2024. Currency figures normalised to ESSA Pharma Inc's reporting currency: US Dollar USD
77.20%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 30 Jun 2024 | 8.75m | 19.72% |
| Bellevue Asset Management AGas of 30 Jun 2024 | 7.89m | 17.78% |
| Soleus Capital Management LP (Investment Management)as of 30 Jun 2024 | 4.21m | 9.49% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 4.18m | 9.41% |
| PFM Health Sciences LPas of 30 Jun 2024 | 2.97m | 6.68% |
| RTW Investments LPas of 30 Jun 2024 | 2.30m | 5.18% |
| Adage Capital Management LPas of 30 Jun 2024 | 1.47m | 3.32% |
| Janus Henderson Investors US LLCas of 30 Jun 2024 | 1.01m | 2.27% |
| Rhenman & Partners Asset Management ABas of 30 Jun 2024 | 806.05k | 1.82% |
| Rock Springs Capital Management LPas of 30 Jun 2024 | 677.01k | 1.53% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
